Purpose
Use LYA-212 response study 37 to identify relevant studies, evaluate participation details, and follow deterministic inquiry pathways.
LYA-212 response study 37
Trial detail provides deterministic protocol context, enrollment progress, and site coverage for transparent participation planning. This page separates informational trial summaries from any regulated communication and clearly labels synthetic content boundaries. The contact workflow creates a traceable request record and logs correlated audit events for governance testing. Users can review eligibility summaries, inspect site status, and submit a study team inquiry.
Type: CorporateLast reviewed: 2026-02-01Owner: LegalStatus: Approved
Trust Boundary
Trial information is deterministic and transparently separates public study context from workflow-driven operations.
Next Steps
Apply filters, review protocol context, and submit inquiry workflows directly from linked study pages.
Page Focus
This page is a child route in the trials section. Use the dedicated detail content below and related route links for deeper navigation.
LYA-212 response study 37
Internal ID: TRL-0037
NCT-like: NCT90000036
Objective: Assess efficacy, safety, and patient-reported outcomes using a controlled synthetic protocol.
Endpoints: Primary endpoint is change from baseline at week 24 with key secondary safety measures.
Timeline: 2022-04-19 to 2026-04-19
Inclusion snapshot: protocol-defined adults with condition-specific disease activity and baseline laboratory eligibility.
Exclusion snapshot: recent conflicting therapies, unresolved safety findings, and protocol-prohibited concomitant conditions.
Site Locations
- Site 37 Medical Center | PI: Dr. Patel | Open
- Site 197 University Hospital | PI: Dr. Patel | Open
- Site 357 Medical Center | PI: Dr. Kim | Open
- Site 517 Community Clinic | PI: Dr. Harper | Open
- Site 677 Medical Center | PI: Dr. Kim | Open
- Site 837 Medical Center | PI: Dr. Kim | Open